Register or Sign in to Save this opportunity, or Send an Inquiry.
Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol_BioSpectrum, Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
The a-bisabolol exhibits improvements os skin-whitening and anti-wrinkle, inhibition of UV radiated hair loss, stimulation of hair growth and anti-obesity
Send an Inquiry

The core technology of BioSpectrum is to provide promising skin-whitening agents.  The α-bisabolol exhibits improvements of skin-whitening and anti-wrinkle, inhibition of UV-irradiated hair loss, stimulation of hair growth and anti-obesity.

Background and unmet needs: Skin color is determined by the accumulation and distribution of melanin which functions to block skin damages caused from the UV irradiation. The activities of tyrosinase is important to the synthesis of melanin. Therefore, the regulation of the activities of tyrosinase is a critical point for skin color.

A multitue of approaches and researches have been made to improve skin conditions but not effectively.

Discovery and Achievements:  The α-bisabolol of BioSpectrum has been developed on the basis of findings that camomile has multiple effects such as anti-inflammation, sedative activities and pain relief and α-bisabolol is a main active component of camomile essence oil.

The α-bisabolol derived from camomile is very effective in improving skin-whitening, anti-wrinkle and anti-obesity. In addition, the α-bisabolol exhibits effects on inhibition of UV-irradiated hair loss and stimulation of hair growth.

The B16 murine melanoma (B-16 F10) was seeded into 6-well plate (1×105 per well) on DMEM and cultured at 37°C in 5% CO2 until above 80%. The α-bisabolol was treated to the samples at a concentration of 1 ppm, 5 ppm and 10 ppm and the samples were observed after 3 days of incubation. The amount of melanin per cells was measured at 490 nm using a microplate reader. The arbutin was served as a comparative agent.

Type of Business Relationship Sought
CN101677925A, CN101677925B, EP2124872A1, EP2124872A4, US20100015071
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833